COMP <GO>
PODD vs MRK // EV/EBITDA & P/E VALUATION
Insulet Corporation (NASDAQ) VS. Merck & Company Inc. Common Stock (new) (NYSE) • 15-METRIC TALLY: PODD 6
— MRK 9
▲ EV/EBITDA & P/E VALUATION LEADER: MRK
LAST: $149.68 (-1.85%) • MKT CAP: $10.58B
valuation
17.1x
LAST: $149.52 (+2.18%) • MKT CAP: $361.02B
valuation
15.3x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (PODD VS. MRK)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | PODD | MRK | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 71.60% | 74.80% | -3.20 | MRK | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 20.40% | 20.70% | -0.30 | MRK | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | 17.1x | 15.3x | +1.80 | MRK | /valuation <GO> |
| Free Cash Flow Yield | 3.57% | 3.42% | +0.15 | PODD | /fcf-yield <GO> |
| Operating Margin | 17.50% | 34.30% | -16.80 | MRK | /operating-margins <GO> |
| Net Profit Margin | 9.10% | 28.10% | -19.00 | MRK | /net-margins <GO> |
| Revenue Growth (YoY) | 30.70% | 1.30% | +29.40 | PODD | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.26% | -2.26 | MRK | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 5.72 | 5.19 | +0.53 | PODD | /balance-sheet <GO> |
| Piotroski F-Score Quality | 8/9 | 7/9 | +1.00 | PODD | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 6.90% | 6.60% | +0.30 | MRK | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 62.4 | 56.9 | +5.49 | PODD | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 0.99 | 0.92 | +0.07 | PODD | /macro-sensitivity <GO> |
| Forward P/E Multiple | 36.0x | 18.4x | +17.60 | MRK | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $10.58B | $361.02B | -$350.44B | MRK | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | PODD REV | MRK REV | PODD GROSS % | MRK GROSS % | PODD FCF | MRK FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $2.71B | $65.01B | 71.6% | 74.8% | $377.7M | $12.36B |
| FY 2024 | $2.07B | $64.17B | 69.8% | 76.3% | $305.3M | $18.10B |
| FY 2023 | $1.70B | $60.12B | 44.0% | 44.0% | $69.3M | $10.30B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
PODD // BETA 0.99
MRK // BETA 0.92